Lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg compared to Rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A10213009" target="_blank" >RIV/61989592:15110/12:10213009 - isvavai.cz</a>
Result on the web
<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5922.2010.00181.x/pdf" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/j.1755-5922.2010.00181.x/pdf</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/j.1755-5922.2010.00181.x" target="_blank" >10.1111/j.1755-5922.2010.00181.x</a>

Result language
angličtina
Original language name
Lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg compared to Rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy
Original language description
EZE/SIMVA was more effective than ROSUVA at lowering LDL-C, TC, non-HDL-C, and apoB in the overall study population and within both subgroups. Numerically, greater between-treatment reductions in LDL-C, TC, non-HDL-C, and apo B were seen in patients withT2DM versus those without T2DM. A significant interaction (P=0.015) was seen for LDL-C indicating that patients with T2DM achieved larger between-group reductions versus those without T2DM. Conclusions: Switching to EZE/SIMVA 10/20 mg versus ROSUVA 10 mg provided superior lipid reductions in patients with/without T2DM.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)